184 related articles for article (PubMed ID: 10099053)
21. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis.
Frank H; Gillen M; Rohatagi SS; Lim J; George G;
J Clin Pharmacol; 2002 Oct; 42(10):1097-104. PubMed ID: 12362923
[TBL] [Abstract][Full Text] [Related]
22. Cardiac effects of ebastine and other antihistamines in humans.
Moss AJ; Morganroth J
Drug Saf; 1999; 21 Suppl 1():69-80; discussion 81-7. PubMed ID: 10597870
[TBL] [Abstract][Full Text] [Related]
23. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects.
Mattila MJ; Kuitunen T; Plétan Y
Eur J Clin Pharmacol; 1992; 43(2):179-84. PubMed ID: 1358620
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry.
Kang W; Liu KH; Ryu JY; Shin JG
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):75-80. PubMed ID: 15556518
[TBL] [Abstract][Full Text] [Related]
25. Myocardial pharmacokinetics of ebastine, a substrate for cytochrome P450 2J, in rat isolated heart.
Kang W; Elitzer S; Noh K; Bednarek T; Weiss M
Br J Pharmacol; 2011 Aug; 163(8):1733-9. PubMed ID: 21410688
[TBL] [Abstract][Full Text] [Related]
26. A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults.
Antonijoan RM; García-Gea C; Puntes M; Valle M; Esbri R; Fortea J; Barbanoj MJ
Clin Drug Investig; 2007; 27(7):453-61. PubMed ID: 17563125
[TBL] [Abstract][Full Text] [Related]
27. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.
Gillen MS; Miller B; Chaikin P; Morganroth J
Br J Clin Pharmacol; 2001 Aug; 52(2):201-4. PubMed ID: 11488779
[TBL] [Abstract][Full Text] [Related]
28. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine.
Tagawa M; Kano M; Okamura N; Higuchi M; Matsuda M; Mizuki Y; Arai H; Iwata R; Fujii T; Komemushi S; Ido T; Itoh M; Sasaki H; Watanabe T; Yanai K
Br J Clin Pharmacol; 2001 Nov; 52(5):501-9. PubMed ID: 11736858
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
30. Absorption, distribution, metabolism and excretion of [14C]ebastine after repeated oral administration in rats.
Fujii T; Tanaka K; Matsumoto S; Hatoyama T; Nomura N; Tagawa M; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):538-43. PubMed ID: 7912072
[TBL] [Abstract][Full Text] [Related]
31. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers.
Frossard N; Benabdesselam O; Purohit A; Mounedji N; Pauli G
Fundam Clin Pharmacol; 2000; 14(4):409-13. PubMed ID: 11030449
[TBL] [Abstract][Full Text] [Related]
32. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers.
Hindmarch ; Shamsi Z
Curr Med Res Opin; 2001; 17(4):273-81. PubMed ID: 11922401
[TBL] [Abstract][Full Text] [Related]
33. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration.
Tagawa M; Kano M; Okamura N; Higuchi M; Matsuda M; Mizuki Y; Arai H; Fujii T; Komemushi S; Itoh M; Sasaki H; Watanabe T; Yanai K
Br J Clin Pharmacol; 2002 Mar; 53(3):296-304. PubMed ID: 11874393
[TBL] [Abstract][Full Text] [Related]
34. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.
Liu KH; Kim MG; Lee DJ; Yoon YJ; Kim MJ; Shon JH; Choi CS; Choi YK; Desta Z; Shin JG
Drug Metab Dispos; 2006 Nov; 34(11):1793-7. PubMed ID: 16896065
[TBL] [Abstract][Full Text] [Related]
35. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group.
Ratner PH; Lim JC; Georges GC
J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1101-7. PubMed ID: 10856142
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
37. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
40. A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity.
Barbanoj MJ; Antonijoan RM; García-Gea C; Morte A; Gich I; Gispert J; Garcia E; Esbrí R; Luria X
Int Arch Allergy Immunol; 2003 Nov; 132(3):263-7. PubMed ID: 14646388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
